Diagnostic tools for cardiac amyloidosis: a pragmatic comparison of pathology, imaging and laboratories


This article was originally published here

Curr Problem Cardiol. 2022 Jan 7:101106. doi:10.1016/j.cpcardiol.2022.101106. Online ahead of print.


Cardiac amyloidosis (CA) is a complex disease considered to be the most common underdiagnosed form of restrictive cardiomyopathy. Accumulation of misfolded proteins called amyloid fibrils in the extracellular space leads to clinical deterioration and late diagnosis is associated with morbidity and mortality. Both types of this disease, light-chain CA and transthyretin-related CA, share many cardiac and extracardiac features that compromise multiple organs such as the kidneys, musculoskeletal system, autonomic nervous system, and brain. gastrointestinal tract. Early diagnosis and detection of CA is imperative. Clinicians should maintain a high degree of suspicion in patients with unexplained diastolic heart failure to implement different disease-modifying therapies in the early stages of the disease. In this article, we have provided a comprehensive review of the multiple invasive and noninvasive cardiac imaging modalities with their respective degrees of sensitivity and specificity.

PMID:35007639 | DOI:10.1016/j.cpcardiol.2022.101106

Source link

Comments are closed.